Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

SNM's joint session with CMOD on molecular imaging biomarkers in clinical research

SNM is collaborating with the International Partnership for Critical Markers of Disease (CMOD) during CMOD's 7th Annual Biomarkers and Surrogate Endpoints Symposium, Bethesda North Marriott Hotel and Conference Center, Bethesda, Md., Oct. 19th, 2009.

3 Oct 2009

People with rare mutations of gene MUTYH at increased risk of bowel cancer

CANCER RESEARCH UK funded scientists have found that people who carry rare mutations within both copies of a gene called MUTYH are 28 times more likely to develop bowel cancer compared to the general population, according to a study in the Journal of Clinical Oncology.

1 Oct 2009

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc. (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in three (3) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection.

1 Oct 2009

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

Halozyme Therapeutics, Inc. today announced additional Phase 2 results that demonstrated faster insulin absorption and increased peak insulin concentrations in type 1 diabetic patients after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with Humulin® R (regular human insulin), a mealtime insulin.

1 Oct 2009

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Integral Molecular, Inc. has been selected by the National Cancer Institute (NCI) to map epitopes for monoclonal antibodies directed against cancer biomarkers. Protein targets of interest to the Clinical Cancer Proteomics community will be analyzed using Shotgun Mutagenesis Mapping technology to identify amino acids that are essential for antibody binding, allowing the discovery and characterization of cancer-specific biomarkers.

1 Oct 2009

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Research published in the October 2009 issue of the Journal of Thoracic Oncology has found an effective combination of positron emission tomography (PET)/computed tomography (CT) (PET/CT) tests to diagnose lung cancer in a "fast-tracked" outpatient setting. This novel approach to the diagnosis of lung cancer demonstrated a high level of sensitivity (97%) and accuracy (82%).

1 Oct 2009

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.

1 Oct 2009

ASCRO adds non-profit organization to the radiation oncology field

The founding members of the American Society of Clinical Radiation Oncology, ASCRO, are very pleased to announce the addition of this professional non-profit organization to the radiation oncology field. ASCRO is primarily dedicated to acquiring a "Provider Status" for clinical radiation oncology physicists.

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Cutting Edge Information hopes to see ill patients have speedier access to potential cures

The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.

1 Oct 2009

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.

1 Oct 2009

ACS NSQIP recognizes Baylor Dallas for achieving exemplary outcomes for surgical patient care

Baylor University Medical Center at Dallas has been recognized as one of 25 hospitals in the nation achieving exemplary outcomes for surgical patient care.

1 Oct 2009

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

1 Oct 2009

Society of Interventional Radiology offers intensive five-day course

The Society of Interventional Radiology presents Catheter Lysis of Thromboembolic Stroke (CLOTS)-an intensive five-day course featuring top interventional radiologists, neurointerventionists, neurologists and neuroradiologists offering doctors the opportunity to gain and/or upgrade skills to incorporate acute ischemic stroke care into their practice.

1 Oct 2009

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Cell Therapeutics, Inc. announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.

1 Oct 2009

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

FASgen, Inc. is pleased to announce that it was awarded a new $1.4 million SBIR Phase II NIH grant for continued research for obesity. FASgen has for some time had extensive research into the effects of inhibition of the fatty acid biosynthesis pathway on the regulation of appetite and weight loss.

1 Oct 2009

Hospira acquires global rights to biogeneric filgrastim from PLIVA

Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska d.o.o. (Zagreb, Croatia) (ZSE: PLVA-R-A), a move that will help extend Hospira's reach and vertical integration in biogenerics. Financial terms of the agreement were not disclosed.

1 Oct 2009

Gamida Cell publishes article evaluating Stemex for leukemia and lymphoma

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo expanded umbilical cord blood cell graft for allogeneic transplantation, written by Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will be published in the November 2009 issue of Expert Opinion on Biological Therapy.

1 Oct 2009

Amicus brief filed against tobacco companies' lawsuit challenging FDA tobacco regulation law

Today, eleven public health and consumer advocacy organizations filed a friend of the court (amicus) brief asking a federal court to reject a lawsuit by R.J. Reynolds, Lorillard and other tobacco companies that seeks to block key provisions of the new federal law regulating tobacco products. The immediate issue before the court is the industry's challenge of a provision that requires FDA approval before tobacco companies can make claims about "modified risk tobacco products."

1 Oct 2009

Social environment plays vital role in breast cancer

Social environment can play an important role in the biology of disease, including breast cancer, and lead to significant differences in health outcome, according to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

1 Oct 2009

Oncology News and Research

Further Reading

SNM's joint session with CMOD on molecular imaging biomarkers in clinical research

People with rare mutations of gene MUTYH at increased risk of bowel cancer

Advaxis announces Phase I trial results of its ADXS11-001 therapeutic cancer vaccine

Phase 2 study of PH20 with regular human insulin confirms faster insulin absorption

NCI selects Integral Molecular to map epitopes for monoclonal antibodies

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

ASCRO adds non-profit organization to the radiation oncology field

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Cutting Edge Information hopes to see ill patients have speedier access to potential cures

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

ACS NSQIP recognizes Baylor Dallas for achieving exemplary outcomes for surgical patient care

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

Society of Interventional Radiology offers intensive five-day course

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

FASgen receives $1.4 million SBIR Phase II NIH grant for obesity research

Hospira acquires global rights to biogeneric filgrastim from PLIVA

Gamida Cell publishes article evaluating Stemex for leukemia and lymphoma

Amicus brief filed against tobacco companies' lawsuit challenging FDA tobacco regulation law

Social environment plays vital role in breast cancer

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News